The Molecular Effects of Ionizing Radiations on Brain Cells: Radiation Necrosis vs. Tumor Recurrence

The central nervous system (CNS) is generally resistant to the effects of radiation, but higher doses, such as those related to radiation therapy, can cause both acute and long-term brain damage. The most important results is a decline in cognitive function that follows, in most cases, cerebral radionecrosis. The essence of radio-induced brain damage is multifactorial, being linked to total administered dose, dose per fraction, tumor volume, duration of irradiation and dependent on complex interactions between multiple brain cell types. Cognitive impairment has been described following brain radiotherapy, but the mechanisms leading to this adverse event remain mostly unknown. In the event of a brain tumor, on follow-up radiological imaging often cannot clearly distinguish between recurrence and necrosis, while, especially in patients that underwent radiation therapy (RT) post-surgery, positron emission tomography (PET) functional imaging, is able to differentiate tumors from reactive phenomena. More recently, efforts have been done to combine both morphological and functional data in a single exam and acquisition thanks to the co-registration of PET/MRI. The future of PET imaging to differentiate between radionecrosis and tumor recurrence could be represented by a third-generation PET tracer already used to reveal the spatial extent of brain inflammation. The aim of the following review is to analyze the effect of ionizing radiations on CNS with specific regard to effect of radiotherapy, focusing the attention on the mechanism underling the radionecrosis and the brain damage, and show the role of nuclear medicine techniques to distinguish necrosis from recurrence and to early detect of cognitive decline after treatment.

[1]  Mahmoud Khaled Abd-Ellah,et al.  A review on brain tumor diagnosis from MRI images: Practical implications, key achievements, and lessons learned. , 2019, Magnetic resonance imaging.

[2]  J. Hodges,et al.  Recent Developments in TSPO PET Imaging as A Biomarker of Neuroinflammation in Neurodegenerative Disorders , 2019, International journal of molecular sciences.

[3]  N. Tandon,et al.  Cerebral Radiation Necrosis: Incidence, Pathogenesis, Diagnostic Challenges, and Future Opportunities , 2019, Current Oncology Reports.

[4]  A. Strafella,et al.  PET Evaluation of Microglial Activation in Non-neurodegenerative Brain Diseases , 2019, Current Neurology and Neuroscience Reports.

[5]  A. Janss,et al.  Guidelines for Treatment and Monitoring of Adult Survivors of Pediatric Brain Tumors , 2019, Current Treatment Options in Oncology.

[6]  C. Zimmer,et al.  The algorithms of adjuvant therapy in gliomas and their effect on survival. , 2019, Journal of neurosurgical sciences.

[7]  L. Ai,et al.  Utility of Dynamic Susceptibility Contrast Perfusion-Weighted MR Imaging and 11C-Methionine PET/CT for Differentiation of Tumor Recurrence from Radiation Injury in Patients with High-Grade Gliomas , 2019, American Journal of Neuroradiology.

[8]  V. Papadopoulos,et al.  Evaluation of the Performance of 18F-Fluorothymidine Positron Emission Tomography/Computed Tomography (18F-FLT-PET/CT) in Metastatic Brain Lesions , 2019, Diagnostics.

[9]  Pierre-Yves Bondiau,et al.  18F-DOPA PET/CT in brain tumors: impact on multidisciplinary brain tumor board decisions , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  M. Argyropoulou,et al.  Radiation Necrosis, Pseudoprogression, Pseudoresponse, and Tumor Recurrence: Imaging Challenges for the Evaluation of Treated Gliomas , 2018, Contrast media & molecular imaging.

[11]  Stuart J. Smith,et al.  Tumour treating fields in a combinational therapeutic approach , 2018, Oncotarget.

[12]  A. Bhatt,et al.  Brain tumour post-treatment imaging and treatment-related complications , 2018, Insights into Imaging.

[13]  Jinming Yu,et al.  Spatial Concordance of Tumor Proliferation and Accelerated Repopulation from Pathologic Images to 3′-[18F]Fluoro-3′-Deoxythymidine PET Images: a Basic Study Guided for PET-Based Radiotherapy Dose Painting , 2018, Molecular Imaging and Biology.

[14]  E. Cohen-Jonathan-Moyal,et al.  Molecular PET imaging in adaptive radiotherapy: brain. , 2018, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[15]  B. Ahn,et al.  Current Radiopharmaceuticals for Positron Emission Tomography of Brain Tumors , 2018, Brain tumor research and treatment.

[16]  S. Lo,et al.  Diagnosis and Management of Radiation Necrosis in Patients With Brain Metastases , 2018, Front. Oncol..

[17]  B. Ertl-Wagner,et al.  Comparison of 18F-GE-180 and dynamic 18F-FET PET in high grade glioma: a double-tracer pilot study , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  M. Strong,et al.  Advances in Neuro-Oncology Imaging Techniques , 2018, Ochsner Journal.

[19]  K. Hoang-Xuan,et al.  Cognitive impairment and morphological changes after radiation therapy in brain tumors: A review. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[20]  Kyle M. L. Jones,et al.  Emerging Magnetic Resonance Imaging Technologies for Radiation Therapy Planning and Response Assessment. , 2018, International journal of radiation oncology, biology, physics.

[21]  N. Tomura,et al.  11C-Methionine Positron Emission Tomography/Computed Tomography Versus 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Evaluation of Residual or Recurrent World Health Organization Grades II and III Meningioma After Treatment , 2018, Journal of computer assisted tomography.

[22]  Karl-Josef Langen,et al.  Update on amino acid PET of brain tumours , 2018, Current opinion in neurology.

[23]  J. Knuuti,et al.  Positron Emission Tomography Imaging of Macrophages in Atherosclerosis with 18F-GE-180, a Radiotracer for Translocator Protein (TSPO) , 2018, Contrast media & molecular imaging.

[24]  A. Mishra,et al.  99mTc-Methionine Hybrid SPECT/CT for Detection of Recurrent Glioma: Comparison With 18F-FDG PET/CT and Contrast-Enhanced MRI , 2018, Clinical nuclear medicine.

[25]  A. Blanco,et al.  Cognitive disability in adult patients with brain tumors. , 2018, Cancer treatment reviews.

[26]  P. Wen,et al.  Imaging Criteria in Neuro-oncology , 2018, Seminars in Neurology.

[27]  Mitchel S. Berger,et al.  Surgical oncology for gliomas: the state of the art , 2018, Nature Reviews Clinical Oncology.

[28]  T. Vannorsdall Cognitive Changes Related to Cancer Therapy. , 2017, The Medical clinics of North America.

[29]  A. Chakravarti,et al.  Diagnostic and Prognostic Significance of Methionine Uptake and Methionine Positron Emission Tomography Imaging in Gliomas , 2017, Front. Oncol..

[30]  S. Ziegler,et al.  TSPO imaging using the novel PET ligand [18F]GE-180: quantification approaches in patients with multiple sclerosis , 2017, EJNMMI Research.

[31]  D. Smart Radiation Toxicity in the Central Nervous System: Mechanisms and Strategies for Injury Reduction. , 2017, Seminars in radiation oncology.

[32]  J. Boxerman,et al.  Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape , 2017, Journal of Neuro-Oncology.

[33]  M. Wiesmann,et al.  O-(2-18F-fluoroethyl)-L-tyrosine PET for evaluation of brain metastasis recurrence after radiotherapy: an effectiveness and cost-effectiveness analysis , 2017, Neuro-oncology.

[34]  N. Albert,et al.  TSPO PET for glioma imaging using the novel ligand 18F-GE-180: first results in patients with glioblastoma , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[35]  W. Heiss Positron emission tomography imaging in gliomas: applications in clinical diagnosis, for assessment of prognosis and of treatment effects, and for detection of recurrences , 2017, European journal of neurology.

[36]  P. Blanchard,et al.  Radiation-induced Neurocognitive Dysfunction in Head and Neck Cancer Patients , 2017, Tumori.

[37]  I. Tsougos,et al.  18F-fluorothymidine PET imaging in gliomas: an update , 2017, Annals of Nuclear Medicine.

[38]  H. Johannesen,et al.  Repeated diffusion MRI reveals earliest time point for stratification of radiotherapy response in brain metastases , 2017, Physics in medicine and biology.

[39]  S. Kitson,et al.  Targeted Therapy Towards Cancer-A Perspective. , 2017, Anti-cancer agents in medicinal chemistry.

[40]  V. Cuccurullo,et al.  Biochemical and Pathophysiological Premises to Positron Emission Tomography With Choline Radiotracers , 2017, Journal of cellular physiology.

[41]  Ian Law,et al.  Clinical PET/MRI in neurooncology: opportunities and challenges from a single-institution perspective , 2016, Clinical and Translational Imaging.

[42]  M. Yamada,et al.  A link between vascular damage and cognitive deficits after whole-brain radiation therapy for cancer: A clue to other types of dementia? , 2016, Drug discoveries & therapeutics.

[43]  J. Kaiser,et al.  Chemotherapy, cognitive impairment and hippocampal toxicity , 2015, Neuroscience.

[44]  M. Adamkov,et al.  Molecular, Cellular and Functional Effects of Radiation-Induced Brain Injury: A Review , 2015, International journal of molecular sciences.

[45]  N. Nonoguchi,et al.  Delayed brain radiation necrosis: pathological review and new molecular targets for treatment , 2015, Medical Molecular Morphology.

[46]  Mark Muzi,et al.  Continuing Education: Multi-modality Brain Tumor Imaging – MRI, PET, and PET/MRI , 2015 .

[47]  S. Miyatake,et al.  Pathophysiology, Diagnosis, and Treatment of Radiation Necrosis in the Brain , 2014, Neurologia medico-chirurgica.

[48]  D. Murray,et al.  Radiation Biology in the Context of Changing Patterns of Radiotherapy , 2014, Radiation research.

[49]  C. Furdui Ionizing radiation: mechanisms and therapeutics. , 2014, Antioxidants & redox signaling.

[50]  V. Cuccurullo,et al.  18FDG-PET/CT in traumatic brain injury patients: the relative hypermetabolism of vermis cerebelli as a medium and long term predictor of outcome. , 2014, Current Radiopharmaceuticals.

[51]  V. Cuccurullo,et al.  Role of PET and SPECT in the Study of Amyotrophic Lateral Sclerosis , 2014, BioMed research international.

[52]  H. Jacene,et al.  Postradiation changes in tissues: evaluation by imaging studies with emphasis on fluorodeoxyglucose-PET/computed tomography and correlation with histopathologic findings. , 2014, PET clinics.

[53]  J. Shinoda,et al.  Comparison of 11C-Methionine, 11C-Choline, and 18F-Fluorodeoxyglucose-Positron Emission Tomography for Distinguishing Glioma Recurrence from Radiation Necrosis , 2013, Neurologia medico-chirurgica.

[54]  R. Banati,et al.  Effects of ionizing radiation on mitochondria. , 2013, Free radical biology & medicine.

[55]  S. Kitson,et al.  Radionuclide antibody-conjugates, a targeted therapy towards cancer. , 2013, Current radiopharmaceuticals.

[56]  E. Shaw,et al.  Neuroanatomical target theory as a predictive model for radiation-induced cognitive decline , 2013, Neurology.

[57]  M. Robbins,et al.  Molecular Pathways: Radiation-Induced Cognitive Impairment , 2013, Clinical Cancer Research.

[58]  J. Hoffman,et al.  Comparison of 18F-Fluorodeoxyglucose and 18F-Fluorothymidine PET in Differentiating Radiation Necrosis From Recurrent Glioma , 2012, Clinical nuclear medicine.

[59]  Andrea Ciarmiello,et al.  PET/MRI and the revolution of the third eye , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[60]  B. Gulyás,et al.  New PET radiopharmaceuticals beyond FDG for brain tumor imaging. , 2012, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[61]  Michelle Monje,et al.  Cognitive side effects of cancer therapy demonstrate a functional role for adult neurogenesis , 2012, Behavioural Brain Research.

[62]  A. Jackson,et al.  Imaging hypoxia in gliomas. , 2011, The British journal of radiology.

[63]  L Junck,et al.  Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. , 2011, The Lancet. Oncology.

[64]  Michael Sabel,et al.  Comparison of 18F-FET PET and 5-ALA fluorescence in cerebral gliomas , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[65]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  Wei Chen,et al.  18F-FDOPA Kinetics in Brain Tumors , 2007, Journal of Nuclear Medicine.

[67]  Wei Chen,et al.  18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[68]  E. Dropcho Central nervous system injury by therapeutic irradiation. , 1991, Neurologic clinics.

[69]  S. Lehnert,et al.  Radiotherapy dose-fractionation schedules. Hyperfractionation and accelerated treatment regimens. , 1991, Neurologic clinics.

[70]  R. Mach,et al.  Development of brain PET imaging agents: Strategies for imaging neuroinflammation in Alzheimer's disease. , 2019, Progress in molecular biology and translational science.

[71]  K. Debatin,et al.  Radiation and Brain Tumors: An Overview. , 2018, Critical reviews in oncogenesis.

[72]  K. Herholz Brain Tumors: An Update on Clinical PET Research in Gliomas. , 2017, Seminars in nuclear medicine.

[73]  Keiji Suzuki [Neurotoxicity of radiation]. , 2015, Brain and nerve = Shinkei kenkyu no shinpo.

[74]  S. Hess,et al.  ¹⁸F-fluorodeoxyglucose PET/computed tomography for primary brain tumors. , 2015, PET clinics.

[75]  G. Marvaso,et al.  The current status of novel PET radio-pharmaceuticals in radiotherapy treatment planning of glioma. , 2014, Current pharmaceutical biotechnology.

[76]  M. Monje,et al.  Cranial radiation therapy and damage to hippocampal neurogenesis. , 2008, Developmental disabilities research reviews.